Infinity Pharmaceuticals Inc was incorporated in California on March 22, 1995 under the name IRORI and, in 1998; the Company changed its name to Discovery Partners International, Inc. On September 12, 2006, Discovery Partners completed a merger with Infinity Pharmaceuticals, Inc., to which a wholly-owned subsidiary of Discovery Partners merged with and into the Company. The Company is a biopharmaceutical company engaged in discovering, developing and delivering medicines to people with difficult-to-treat diseases. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. The IPI-145, its primary product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K. The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in white blood cells, where they have distinct and mostly non-overlapping roles in immune cell development and function. For Hematologic Malignancies, the Company has launched DUETTS, an investigation of IPI-145 in blood cancers. As part of the DUETTS program, it is conducting DYNAMO, a Phase 2, open-label, single arm study evaluating the safety and efficacy of IPI-145 dosed at 25mg BID in approximately 120 patients with indolent non-Hodgkin lymphoma, or iNHL, including follicular lymphoma, marginal zone lymphoma and small lymphocytic lymphoma, whose disease is refractory to radio immunotherapy or both rituximab and chemotherapy. The FDA has granted orphan drug designation to IPI-145 for the potential treatment of follicular lymphoma. It is conducting DUO, a randomized, monotherapy Phase 3 study of IPI-145 in approximately 300 patients with relapsed/refractory chronic lymphocytic leukemia. For Inflammation and Autoimmune Diseases, the Company has completed a Phase 1, randomized, double-blind, placebo-controlled trial of IPI-145 in healthy adult subjects designed to support the development of IPI-145 in inflammatory and autoimmune diseases. The Company is also developing its second PI3K product candidate, a potent, oral inhibitor of PI3K-delta and gamma referred to as IPI-443. The nonclinical studies of IPI-443 required for Phase 1 development have been completed, and the data from the two Phase 2 studies of IPI-145 in inflammatory and autoimmune diseases will guide the next steps for the development of IPI-443. The Company has discovered IPI-940, a novel, orally available inhibitor of fatty acid amide hydrolase. It is believed that inhibition of FAAH may enable the body to bolster its own analgesic and anti-inflammatory response and may have applicability in a broad range of painful or inflammatory conditions. The Company has five issued or allowed U.S. patents covering IPI-145 and/or other molecules related to PI3K program, which expires on various dates between 2029 and 2031. In addition, it has approximately 170 patents and patent applications pending related to PI3K program.